US pharmaceutical pricing and regulatory shifts

The United States pharmaceutical landscape is undergoing significant shifts driven by regulatory scrutiny and new pricing legislation. Initially, focus centered on the pharmacy benefit management (PBM) industry, where plan sponsors and agencies like the Federal Trade Commission (FTC) have pushed for greater transparency regarding prescription drug costs and fee disclosures.

As legislative frameworks like the Inflation Reduction Act and the GLOBE drug pricing model take effect, pharmaceutical manufacturers are adjusting their business strategies. To navigate price negotiations and regulatory changes, executives are considering onshoring production, increasing overseas pricing, and shifting investments toward biologics.

Furthermore, the implementation of specific pricing models has led to significant revisions in government projections. Due to exemptions granted to major firms such as Pfizer, Eli Lilly, and Novo Nordisk, the Department of Health and Human Services (HHS) has lowered its estimated Medicare Part B savings from an original $11.9 billion to approximately $440 million.